|Issuer:||IDERA PHARMACEUTICALS, INC. (IDRA)|
|Original Submission Date:|
C/O IDERA PHARMACEUTICALS, INC.
505 EAGLEVIEW BOULEVARD, SUITE 212 EXTON, PA 19341
|Title of Security||Transaction Date||2a. Deemed Execution Date||Transaction Code||Shares||Acquired or Disposed||Price per share||5. Amount of Securities Beneficially Owned Following Reported Transaction||6. Ownership Form Direct or Indirect||Nature of Indirect Ownership|
|Title of Derivative Security||Conversion or Exercise Price of Derivative Security||Transaction Date||Deemed Execution Date||Transaction Code||Number of Derivative Securities Acquired (A) or Disposed of (D)||Date Exercisable||Expiration Date||Title and Amount of Securities Underlying Derivative Security||Price of Derivative Security||Number of derivative Securities Beneficially Owned Following Reported Transaction(s)||Ownership Form: Direct (D) or Indirect (I)||Nature of Indirect Beneficial Ownership|
|STOCK OPTION (RIGHT TO BUY)||1.11||2021-07-08||deemed execution date||A||124,000 (a)||2031-07-08||common stock 124,000||$1.11||124,000||direct|
|f1||the stock option award was granted under the issuer's 2013 stock incentive plan. the stock option vests and becomes exercisable over a four-year period commencing on july 8, 2021. twenty-five percent (25%) of the stock option vests and becomes exercisable on july 8, 2022 (first anniversary of the date of grant) and the balance vests in twelve equal quarterly installments over the remaining three years of the four-year period, subject to continued service with the issuer.|